Definition
Despite promising early results, MDMA-assisted therapy research still cannot tell us with confidence about long-term outcomes, generalizability across populations, therapist effects, comparative efficacy against extended standard care, and real-world access.
Why it matters
Honest limits protect patients from misplaced certainty and protect the field from over-promising.
The Science
Regulatory review has emphasized the need for larger, longer, and more diverse studies. Methodological questions around blinding, expectancy, and therapist variability remain open.
The NSI Perspective
NSI is careful about the difference between a promising signal and a settled finding. This field is in between.
Clinical Implications
Clinicians should be able to speak candidly about what remains unknown. Anyone who cannot is not communicating fully.
Practical Application
Ask providers what they still do not know. The quality of the answer tells you about the quality of the practice.
References
- 1.FDA Advisory Committee documents on MDMA-assisted therapy; 2024.